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Edited by Robert B. RussellAbstract The non-synonymous SNPs (nsSNPs) in coding re-
gions, neutral or deleterious, could lead to the alteration of the
function or structure of proteins. We have developed the compu-
tational models to analyze the deleterious nsSNPs in the trans-
porters and predict ones in ABCB (ATP-binding cassette B)
transporters of interest. The RPLS (ridge partial least square)
and LDA (linear discriminant analysis) methods were applied
to the problem, by training on a selection of datasets from a spec-
iﬁed source, i.e., human transporters. The best combination of
datasets and prediction attributes was ascertained. The predic-
tion accuracy of the theoretical RPLS model for the training
and testing sets is 84.8% and 80.4%, respectively (LDA:
84.3% and 80.4%), which indicates the models are reasonable
and may be helpful for pharmacogenetics studies.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Single nucleotide polymorphisms (SNPs), which are found
every 200–300 bp, represent the most abundant class of genetic
variations in the human genome [1]. Up to June 17, 2006,
24910873 SNPs have been deposited to public databases
(NCBI dbSNP Build 126) [2]. Non-synonymous SNPs
(nsSNPs), which cause the changes of amino acid residues in
proteins, account for almost half of all DNA mutations and
may be functionally neutral or deleterious [3]. The disease-
causing variations may cause deleterious eﬀects on proteins:
they may inactivate the functional sites or interact sites of
enzymes or impact the folding of proteins; they may signiﬁ-
cantly destabilize the stability of proteins, or change the solu-Abbreviations: SNP, single nucleotide polymorphism; nsSNPs, non-
synonymous SNPs; ABCB, ATP-binding cassette B; RPLS, ridge
partial least square; LDA, linear discriminant analysis; 3D, 3-dimen-
sional; SIFT, sorting intolerant from tolerant; DDG, relative stability
changes; ADME/T, absorption, distribution, metabolism, excretion
and toxicity; DDI, drug–drug interaction; SVR, support vector
regression; RSA, relative solvent accessibility; ASA, accessible surface
area; ECEPP, the empirical conformational energy program for
peptides algorithm; MCC, Matthew’s correlation coeﬃcient; BER,
balanced error rate; TM, transmembrane
*Corresponding author. Fax: +86 411 84676961.
E-mail address: yling@dicp.ac.cn (L. Yang).
0014-5793/$32.00  2006 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2006.11.047bility of proteins [4–6]. Moreover, mutation sites at the N and
C termini (or even within domains) often lead to diﬃculties in
the protein expression, puriﬁcation and crystallization [7], and
are hence diseases associated.
Discovering the deleterious mutations is the mainly task of
pharmacogenomics and pharmacogenetics. It is well known
that mining them from dbSNP database is a laborious project
only by site directed mutagenesis experiments and gene knoc-
kout/knockin experiments with more and more nsSNPs data
available. Therefore, a primary challenge currently is that
how to accurately predict those potentially deleterious
nsSNPs. Several groups have tried to evaluate the deleterious
nsSNPs based on 3-dimensional (3D) structure information
of proteins (or homologous structures) in silico. Karchin
et al. considered that the strongest predicting signals in
the lac repressor/lysozyme set were solvent accessibility and
superfamily-level evolutionary conservation [8]. Sunyaev
et al. and Chen et al. also indicated that the residue solvent
accessibility, which could identify the buried residues, was con-
ﬁdently proposed as predictors of deleterious substitutions
[5,9].
However, the theoretical prediction methods for deleterious
nsSNPs are still in its infancy since the 3D structural infor-
mation of most proteins are still unavailable [10–12]. There-
fore, it is a consequentially trend to predict the deleterious
variations of proteins using sequence-based and position-spe-
ciﬁc evolutionary information [5,13,14]. The homology-based
algorithm, SIFT (Sorting Intolerant From Tolerant) developed
by Pauline et al. [14,15], was used to predict the conservation
indices of all 20 possible amino acids at a given position
according the ortholog sequences and determine which
nsSNPs would be intolerant variations. Some other methods
based on Site Entropy calculations, relative stability changes
(DDG) were also developed for predicting deleterious nsSNPs
[14,16,17]. These methods based on protein sequence have
been demonstrated that the accuracy is the same as other
methods using tertiary structure information [17].
The relationships between the genotype and phenotype of
nsSNPs in transporters have received a plenty of research
attentions because of their prevalence in the drug responses
and close association to many inherited diseases. Transporters
could medicate a wide range of fundamental biological pro-
cesses, such as the cell signaling, transport of membrane-
impermeable molecules, cell–cell communication, cell adhesion
and recognition [18,19]. The ATP-binding cassette B (ABCB/
MDR/TAP) transporter subfamily includes 11 members and
is unique in mammals in that it contains both the full and half
transporters [20]. Both in vitro and in vivo studies haveblished by Elsevier B.V. All rights reserved.
Table 1
Distribution of nsSNPs in ABCB transporters
Member Length(Aa) Pro_ID No. nsSNP
ABCB1 1280 2506118 28 (18)
ABCB2 808 9665248 16 (8)
ABCB3 686 549044 16 (3)
ABCB4 1279 126932 13 (9)
ABCB5 812 36413607 4 (0)
ABCB6 842 13123949 6 (0)
ABCB7 752 8928549 7 (5)
ABCB8 718 6005804 6 (1)
ABCB9 766 22095458 2 (1)
ABCB10 738 22095459 2 (1)
ABCB11 1321 12643301 21 (10)
No. nsSNP means the number of the nsSNPs in ABCB transporters.
The number in each bracket refers to the number of neutral or del-
eterious nsSNPs already known according to Swiss-Prot or literatures.
Table 2
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role inﬂuencing the ADME/T processes (absorption, distribu-
tion, metabolism, excretion and toxicity) of a wide variety of
drugs, and are also one reason to induce the drug–drug inter-
action (DDI) in humans [21]. ABCB1 (MDR1/PGY1), the ﬁrst
human ABC transporter cloned, could transport several hun-
dreds drugs and confer cancer multidrug resistance [22]. The
nsSNPs of ABCB4 and ABCB11, located in the liver, are
mainly reasons for the deregulation of the hepatobiliary circu-
lation and correlative diseases with the cholestasis [23]. The
variations of ABCB2 (TAP1) and ABCB3 (TAP2) proteins
could lead to immunodeﬁciency [24,25]. The variations of four
half transporters, ABCB6, ABCB7, ABCB8, and ABCB10,
localized in the mitochondria and involved in iron metabolism,
could baﬄe the transport of Fe/S complex into cytoplasm [26].
ABCB5, a novel drug transporter and chemoresistance media-
tor, determines the membrane potential and regulates the cell
fusion in the physiologic skin progenitor cells [27]. The ABCB9
half transporter, which is the closest homolog of the TAPs, has
been localized to lysosomes [26]. The wealth of pharmcogenet-
ical studies revealed that most common diseases clusters, such
as the ulcerative colitis (UC), progressive familial intrahepatic
cholestasis (PFIC) syndromes, systemic lupus erythematosus
(SLE), rheumatoid arthritis (RA), ankylosing spondylitis, sid-
eroblastic anemia, insulin-dependent diabetes mellitus, chol-
estatic liver and so on, are partially responsible for the
variations of ABCB transporters, more information as shown
in (http://www.tcdb.org/disease_explore.php) [21–27]. With
increasing knowledge of the properties of ABCB transporters
now, it is feasible to predict the phenotype of an nsSNP from
the genotype by in silico methods.
Deleterious nsSNPs analyses for the transporters have not
been estimated computationally till now, although they have
received great focus from experimental researchers. Therefore,
in this work, the computational models were built to analyze
the deleterious nsSNPs in the transporters, and were used to
predict the deleterious ones in the ABCB subfamily. Up to
our knowledge, it is still diﬃcult to obtain the whole 3D struc-
ture information of most human transporters, including the
ABCB transporters, thus resulting in the diﬃculties of building
computational models based on their 3D structures. In order
to overcome the barriers, we have developed sequence-based
models combined with some predicted structure information
for all transporters in the datasets. The testing sets including
121 nsSNPs of ABCB transporters and the training sets inclu-
ding 762 nsSNPs of other transporters were carefully built, and
a ridge partial least square (RPLS) analysis derived tool has
been applied to predict the disease-causing variations in the
datasets. As a comparison to the RPLS, the linear discriminant
analysis (LDA) method has also been used in building models.The families of the 138 transporters in the training sets
Human transporter
family
Deleterious training set Neutral training set
Members Members
Potassium channels 10 11
Calcium channels 0 2
Annexins 0 1
Sodium channels 24 42
Solute carriers 8 17
ATPase 6 8
Amino acid
transporters
2 4
Others 0 32. Materials and methods
2.1. Datasets
All the transporter IDs were collected from the TCDB database with
classiﬁcation information (http://www.tcdb.org/hgnc_explore.php), the
detailed description about polymorphism and protein sequence were
obtained by the Swiss-Prot database [28] and NCBI human genome
protein sequence [2].
The databases of Swiss-Prot sequence variants provide full inform-
ation of classiﬁcation about nsSNPs associated with a given Swiss-Prot
entry (Release 49.1 of 21-Feb-2006) [28]. All the variants in the data-base are therefore labeled as disease, unclassiﬁed or polymorphism,
respectively, which have been demonstrated by a variety of reports
[28]. Mutations in transporters labeled as disease or polymorphism
used in this work were collected from the Swiss-Prot database. The
mapped nsSNP was kept where the amino acid was the same in both
the Swiss-Prot protein sequence and the NCBI human genome protein
sequence [2]. All the transporters applied in this work lack the whole
3D structure information, which is limited from 350 to 1500 amino
acids in length. The length restriction of sequence in training sets
is made to build a more reasonable dataset, since all the ABC trans-
porters (testing sets) are relatively large proteins, ranging from 686
to 1321, as shown in Table 1.
2.1.1. Training sets.
I. Deleterious variations dataset: 540 nsSNPs were collected from 50
transporters of ﬁve families (Table 2). Deleterious variations were
labeled as disease in the Swiss-Prot database.
II. Neutral variations dataset: 222 nsSNPs were collected from 88
transporters of eight families (Table 2). Neutral variations were la-
beled as polymorphism in Swiss-Prot database.
2.1.2. Testing sets. One hundred and twenty-one nsSNPs in ABCB
transporters were extracted from the above databases and literature
[2,21–29]. In this dataset, the 56 nsSNPs have already been known
as phenotypes, neutral and deleterious according to the literature
information, as shown in Table 1.
2.2. Candidate features
2.2.1. Evolutionary-conservation features.
I. SIFT score. PSI-BLAST in SIFT was used to search against the
EMBL non-redundant protein database for homologous sequences
and to build a multiple sequence alignment (MSA). It could compute
the frequency of the amino acid a occurring at position i (fia) in MSA.
The fia is given as a score ranging from 0.0 to 1.0, and the nsSNP
whose score is less than 0.05 is considered to be deleterious. A median
sequence conservation score of 63.25 is considered as reasonable accu-
racy and the correspondingly sequence diversity is adequate. In gen-
eral, for the protein sequence, SIFT performs MSA until a median
sequence conservation score for the sequence is reached at the default
of 3.0 and whether a substitution with any of the other amino acids is
6802 Y. Li et al. / FEBS Letters 580 (2006) 6800–6806tolerant or intolerant for every position in the proteins. The SIFT ver-
sion 2.0 was used for the analyses in this work [15].
II. Site entropy. It was used for measuring the sequence variability
and calculated based on the entropy-based equation given as follows
[17]:
CeðiÞ ¼
X20
a¼1
faðiÞ ln faðiÞ
where Ce(i) is the entropy with the reverse sign at position i, fa (i) rep-
resents the frequency of the amino acid ‘a’ at ith position obtained
from MSA within ortholog sequences. We have developed a program
to calculate Site Entropy according to this formula using C language.
2.2.2. Structural features.
I. Relative solvent accessibility (RSA). The RSA of amino acid res-
idue i was deﬁned as the ratio of its solvent-exposed surface area ob-
served in a given structure (SAi) and the maximum achievable
solvent exposed surface area for this amino acid (MSAi):
RSAi ¼ SAi
MSAi
 100%
RSAi can hence adopt values from 0% to 100%, with 0% correspond-
ing to a fully buried and 100% to a fully accessible residue, respectively.
In this study, the real value of RSA parameter was obtained for each
residue using the threshold of 25% [30].
II. Solvent accessible surface area (ASA). The solvent accessible sur-
face is deﬁned as the locus of the centre of a probe sphere (representing
the solvent molecule) as it rolls over the van der Waals’ surface of the
protein. A two-stage support vector regression (SVR) approach is pro-
posed to predict the real values of ASA from the position speciﬁc scor-
ing matrices generated from the PSI-BLAST proﬁles by using the MSA
information [12].
2.2.3. Sequence-based features. I. Protein stability changes: DDG. A
direct prediction of the value of DDG can be used to infer the directions
of mutations. A statement of whether the protein stability is predicted
to be increased or decreased by the mutation, and a conﬁdence. If the
DDG is positive, the mutation increases stability and is classiﬁed as a
positive example. If DDG is negative, the mutation is destabilizing
and is classiﬁed as a negative example. A score near 0 means un-
changed stability. A score near 1 means high conﬁdence in decreased
stability. A score near +1 means high conﬁdence in increased stability
[16].
2.2.4. Physicochemical properties of amino acids. All changes of the
physicochemical properties and their absolute values were analyzed
using both the RPLS and LDA methods. The relevant calculation pro-
grams were compiled by C language.
I. Volume calculations (DV). The average standard residue volumes
were collected from Gerstein et al [31]. The changes in volume, DV,
were evaluated using the following expressions for substitutions:
DV ¼ V wild-type  V variant
Here, V is the volume of each amino acid. Vvariant refers to the volume
pertaining to amino acid causing substitution and Vwild-type refers to
the volume of the amino acid in the native protein.
II. Extended state ASA calculations. The extended state ASA was
calculated using ECEPP/2 algorithm (the empirical conformational en-
ergy program for peptides algorithm) with dihedral angles given in an
extended tripeptide Ala-X-Ala/Gla-x-Gla conformation [32].
III. DDGh calculations. DG

h (kcal/mol) of hydration was computed at
298 K for the N-acetyl-N 0-methylamides of the 20 naturally occurring
amino acids [33].
IV. Amino acid scales (Swiss-Prot) calculations [28]. An amino acid
scale is deﬁned as a numerical value assigned to each type of amino
acid. In this work, the scales used in our calculations were as follows
(each scale was represented by its abbreviation in the bracket):
Changes in hydrophobicity (CH); average area buried on transfer
from standard state to folded protein (AAB); free energy of transfer
from inside to outside of a globular protein (FE); hydration potential
at 25 C (HP); hydrophobicity scale based on free energy of transfer
(kcal/mol) (HE); hydrophilicity (HH); hydrophobicity scale (pi-r)
(HS); normalized consensus hydrophobicity scale (NCH); optimized
matching hydrophobicity (OMH); refractivity; average ﬂexibility index
(AFI); recognition factors (RF); bulkiness; molecular weight of each
amino acid (MW); PG and PZ represent two types of polarity param-
eter according to Zimmerman and Grantham, respectively.2.2.5. Other features.
I. DISpro: ordered or disordered [34]: The residue is ordered if a
score <0.5. Otherwise, the residue is disordered if a score >0.5.
The DISpro score was used to judge a nsSNPs to be deleterious
or neutral.
II. DIpro: disulﬁde bridges [34]: If a mutation is located in the disul-
ﬁde bridges, it would be thought to be deleterious.
III. Secondary structure: disease-associated nsSNPs also have a
slightly diﬀerent secondary structure propensity, which tend to
occur at b-sheet sites [35].
VI. The mutations located in those places described as binding or ac-
tive sites in the Swiss-Prot database are more likely to be delete-
rious.
V. The variant involves a Pro/Gly residue in the helix or turn sites
also tends to be deleterious [5,8].
2.3. Mathematical tools
A recently developed algorithm combining partial least squares
(PLS) and ridge penalized logistic regression was used. The procedure
is an integration of the regularization step (ridge penalty) and the
dimension-reduction step (PLS).
As a detailed implementation has been given elsewhere [36], here, we
only give a brief description of this method. RPLS divides in two steps:
1: ðZ1;W 1Þ  RIRLSðy;X ; kÞ;
2: cPLS;j  WPLSðz1;X ;W 1;jÞ:
Let k be some positive real constant and j be some positive integer.
RPLS depends on the two parameters, k and j. k is determined at
the end of Step 1, as minimizing the BIC criterion (see the Ridge pen-
alty section), and thus independently of j. The predictive performance
of the resulting classiﬁcation rule is illustrated on the datasets in this
work. The question of classiﬁcation in high dimensional setting can
be eﬀectively addressed by means of this method.
As a comparison to the RPLS, the LDA method was also applied
into these datasets. The stepwise selection method has been used in
building the LDA model. The aim of stepwise selection is to look alt-
ernantely out several crucial features for diﬀerentiating two classes
among all parameters. The coeﬃcients of features in the regression
equation were calculated by LDA, and they can somewhat describe
the importance of the features in the LDA model. Building regression
equation is the process to evaluate the parameters (partial regression
coeﬃcient) in the regression model. According to the absolute value
of the coeﬃcients (b1, b2 . . . bp) before the dependent variables, it is
easy to know the contributions of each parameters in the optimized
LDA equation:
y^i ¼ b0 þ b1x1 þ b2x2 þ    þ bpxp
An internally developed C language programs have been applied for
this work.
2.4. Model assessments
Matthew’s correlation coeﬃcient (MCC), a rigorous statistical mar-
ker, was used to evaluate the prediction accuracy in our study, given by
MCC ¼ ðTP TN FP FNÞﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃðTNþ FNÞðTNþ FPÞðTPþ FNÞðTPþ FPÞp
The MCC ranges from 1 to 1, where TP is the deleterious number of
true positives, TN is the neutral number of true negatives, FP is the
neutral number of false positives and FN is the deleterious number
of false negatives. Moreover, we also evaluated our results using bal-
anced error rate (BER) [37]:
BER ¼ 1
2
 FN
TPþ FN
 
þ 1
2
 FP
TNþ FP
 
Moreover, the eﬀectiveness of our models is measured in the terms of
sensitivity, speciﬁcity, error rate and accuracy [38]:
 Sensitivity is the percentage of relevant point mutations identiﬁed
by TP/(TP + FN).
 Speciﬁcity is the percentage of correct point mutations validated by
TN/(TN + FP).
 Error rate is the percentage of wrong decisions made by (FP + FN)/
total extracted.
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(TP + TN)/total extracted.
It is clear, therefore, that any single number that represents the pre-
dictive power of the methods should account for all of the possibilities
listed above.Table 43. Results
3.1. RPLS and LDA models
RPLS and LDA methods were employed to build several
models for the 762 nsSNPs of the datasets, which were col-
lected from all of the transporters without 3D structures in
Swiss-Prot. In the optimized models, the RPLS analyses re-
vealed that 500 of totally 540 known deleterious nsSNPs and
146 of totally 222 known neutral nsSNPs were correctly pre-
dicted in the training sets, respectively. In the testing sets,
RPLS analyses revealed that the 21 (total = 22) known delete-
rious nsSNPs and 20 (total = 29) known neutral nsSNPs were
correctly predicted, respectively. For the LDA method, the TP
and TN were 479 and 163 for the same training sets. The TP
and TN were 19 and 22 using LDA method for the same test-
ing sets as shown in Table 3a.
3.2. Assessment of the models
In the RPLS model, the sensitivity, speciﬁcity, accuracy,
MCC and BER were 92.6%, 65.8%, 84.8%, 0.617 and 0.208
for the training sets, respectively. Correspondingly, they were
95.5%, 69.0%, 80.4%, 0.648 and 0.178 for the testing sets,
respectively. On the other hand, the sensitivity, speciﬁcity,
accuracy, MCC and BER for the LDA model were 88.7%,
73.4%, 84.3%, 0.620 and 0.189, respectively, in the training
sets. Correspondingly, they were 86.4%, 75.9%, 80.4%, 0.616Table 3a
Analysis results of LDA and RPLS
Sets Methods TN TP FN FP Total
a.
Training RPLS 146 500 40 76 762
LDA 163 479 61 59
Testing RPLS 20 21 1 9 51
LDA 22 19 3 7
LDA: linear discriminant analysis; RPLS: ridge partial least squares
TN (true negative): a neutral match that correctly recognized as neu-
tral nsSNP by discriminators; TP (true positive): a deleterious match
correctly recognized as deleterious nsSNP by discriminators; FN (false
negative): a deleterious match that incorrectly recognized as neutra
nsSNP by discriminators; and FP (false positive): a neutral match that
incorrectly recognized as deleterious nsSNP by discriminators
respectively.
Table 3b
Analysis results of LDA and RPLS
Sets Methods Se (%) Sp (%)
b.
Training RPLS 92.6 65.8
LDA 88.7 73.4
Testing RPLS 95.5 69.0
LDA 86.4 75.9
Se, Sp, Er and Ac mean the sensitivity, speciﬁcity, error rate and accur
means the balanced error rate.
Distribution of the deleterious nsSNPs predicted in ABCB transporters
Member Number nsSNPs
ABCB1 5 G185V, A599T, G1063A, I1145M, G1265S
ABCB2 4 L170V, S346F, A430V, P576L
ABCB3 4 L79P, T257I, A374T, A609V
ABCB4 2 A1100T, I1185V
ABCB5 1 A470T
ABCB6 2 L293V, V310F
ABCB7 0
ABCB8 3 S39N, R304C, S560C
ABCB9 1 V296G
ABCB10 1 R242G
ABCB11 5 V284L, R432T, Q558H, G1004D, E1186K
nsSNPs: the left capital letter in each nsSNPs is the abbreviation of the
wild-type amino acid in certain protein; the middle ﬁgure in each
nsSNPs is the position where the variation happens in the protein; the
right capital letter in each nsSNPs is the abbreviation of variation
amino acid in the protein, e.g. G185V in ABCB1 means that the amino
acid Gly (G) mutates into the Val (V) at the position 185 in ABCB
transporter..
l
,acy, reand 0.189, respectively, for the testing sets as shown in Table
3b.
3.3. ABCB transporters
Among the 56 known deleterious or neutral nsSNPs in dif-
ferent ABCB transporters, several nsSNPs were consistently
predicted as deleterious by two models, which were consistent
with the experimental results in the reports [39–41]. And they
are S704R, G705R, G706S/D in ABCB2 (TAP1), A565T,
T665A in ABCB3 (TAP2), and I498T in ABCB11 (ABCBB).
In addition, three other nsSNPs, the G185V in ABCB1,
V284L and G1004D in ABCB11, which have been still unclas-
siﬁed in the Swiss-Prot [28], were consistently predicted as del-
eterious in this work. Interestingly, ﬁve nsSNPs, whose
diseases-causing phenotype was always a disputed issue [42–
45], were predicted as deleterious in our study as the
K433M, A893T and K1076M in ABCB1, the R150K in
ABCB4 and the Y343H in ABCB11. Because of the diﬀerent
experimental techniques used, the criteria for labeling a residue
as a site of deleterious mutations were somewhat diﬀerent. For
both the RPLS and LDA models, 28 nsSNPs, distributed
in the ABCB transporters with the exception of ABCB7,
have been consistently evaluated to be deleterious as shown
in Table 4.
3.4. Variations of amino acids
Fig. 1 shows the ratio of the top-eight ranked amino acids of
variations in the datasets. Those amino acids were R, G, P, L,Er (%) Ac (%) MCC BER
15.2 84.8 0.617 0.208
15.7 84.3 0.620 0.189
19.6 80.4 0.648 0.178
19.6 80.4 0.616 0.189
spectively. MCC means the Matthew’s correlation coeﬃcient and BER
00.02
0.04
0.06
0.08
0.1
0.12
0.14
A A R R G G L L S S T T V V P I
Amino acids
R
at
es
Fig. 1. The composition rates of the top-eight ranked variation amino
acids in the deleterious and neutral training sets. The blue amino acids
are of the deleterious set and the red amino acids of the neutral one.
6804 Y. Li et al. / FEBS Letters 580 (2006) 6800–6806V, S, A and T in the deleterious set and V, I, T, A, R, L, S and
G in the neutral set, respectively.4. Discussion
The functional analysis of nsSNPs may oﬀer the lead to
understand the genetic diﬀerences between individuals and dis-
ease states, and eventually improve the medical treatments by
allowing the prediction of genetically related disease risk and
drug response [46]. Therefore, the computational prediction
of deleterious nsSNPs is of great importance and will promote
the development of the pharmacogenetics and pharmacoge-
nomics. At the protein structure level, the in vitro experimental
data have shown that the deleterious nsSNPs might contribute
to the changes of the structure, stability and function of pro-
teins [37]. At the amino acid sequence level, the deleterious
nsSNPs might be expected to produce the least conservative
replacements [15]. Therefore, it is feasible to predict the delete-
rious nsSNPs using diﬀerent mathematic methods. In this
work, the parameters of position-speciﬁc phylogenetic features
were ﬁrstly calculated and used to predict deleterious nsSNPs
in the transporters applying RPLS and LDA methods, com-
bining predicted structure features, sequence-based features
and physicochemical properties of amino acids.
4.1. Performance of LDA and RPLS
The prediction accuracy of a theoretical model usually de-
pends on two factors: the superior machine learning approach
and informative predictors [37]. In this work, a new method,
i.e., RPLS and a conventional one, i.e., LDA were employed
to build the models. Our results demonstrated that both the
methods are applicable for the models.
In order to validate the performance of the models, several
calculations were also carried out on the two models, i.e., the
sensitivity, speciﬁcity, accuracy, error rate, MCC, and BER.
The sensitivity shows that the RPLS is better than the LDA
for the deleterious sets (RPLS: 92.6% (training) and 95.5%
(testing) versus LDA: 88.7% (training) and 86.4% (testing)),as shown in Table 3b. However, the speciﬁcity shows that
the LDA is somewhat better than the RPLS for the neutral sets
(LDA: 73.4% (training) and 75.9% (testing) versus RPLS:
65.8% (training) and 69.0% (testing)). Therefore, we can com-
bine the RPLS and LDA to predict the phenotype of the
nsSNPs in the transporters.
MCC has been widely used as an evaluation criterion of ma-
chine learning performance in bioinformatics studies. More-
over, MCC was a better evaluation criterion than the overall
accuracy in that there was a disparity in the number of positive
samples and negative ones. The values of the MCC (RPLS:
0.617 and 0.648 versus LDA: 0.620 and 0.616) indicate that
the RPLS is slightly better than the LDA. One explanation
may be that RPLS model is more robust than the LDA model
for unbalanced datasets.
On the other hand, if there are biases in certain samples of
the datasets, BER would take into account the varying class
size distributions and assume equal weights of the prediction
errors for deleterious and neutral samples. Moreover, BER is
also an alternative solution to the problem when the prediction
model is highly estimated through the calculation of the overall
accuracy of prediction [37]. In our study, BER were 0.208 and
0.178 for the RPLS model and 0.189 and 0.189 for the LDA
one (as shown in Table 3), which also validate the good perfor-
mance of the models.
Our accuracy was 84.8% and 84.3% in this work for the
RPLS model and the LDA ones respectively, an improvement
over previously published [11,37]. The main reason is that all
the datasets we used are transporters, thus leading to certain
similarities between the training and testing sets. Moreover,
all the sequences of the proteins are limited in length from
350 to 1500. However, it may also lead to decrease the gener-
alization ability of the models for non-transporters.
4.2. Candidate features
The RPLS is a combination method of partial least squares
and ridge penalized logistic regression, therefore it seems to be
diﬃcult to directly ﬁnd the crucial features among the original
ones to build a model by only using RPLS. In contrast, LDA,
appearing complementary to the RPLS, is tractable to the cru-
cial features in the model by using the stepwise method.
Through an analysis of LDA equation, it is easy to explain
the impacts of diﬀerent features on the LDA model. Here,
based on our resulted LDA equation, the candidate features
are described as follows:
Y ¼ 0:557 SIFT 0:341 Site entropyþ 0:225 DDG
 0:445ASAþ 0:381RSAþ 0:386DISpro
 0:136 FEþ 0:126OMHþ 0:173 PZ
þ 0:341 Bulkiness ð1Þ
4.2.1. Position-speciﬁc phylogenetic features. The phyloge-
netic estimators could quantify how well conserved a given
amino acid is at a speciﬁc position in a protein [15]. The SIFT
score and Site Entropy describe the conservation of an amino
acid at a speciﬁc position in a sequence. In Eq. (1), the coeﬃ-
cients for the position-speciﬁc phylogenetic features are 0.557
and 0.341, respectively, indicating the importance of the pre-
dictors. These results also show the validity of SIFT in the pre-
diction of deleterious nsSNPs, which is consistent with certain
previous research [14,15].
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acid residues, important for both the structure maintaining
and functioning of proteins. The residues whoever identiﬁed
as buried using the solvent RSA are conﬁdently deleterious
[9]. Two algorithms for predicting the RSA and ASA were
used in this study, which were signiﬁcant improvements over
previously published tools [12,30]. The coeﬃcients of ASA
and RSA in Eq. (1) are 0.445 and 0.381,respectively, reveal-
ing that they are both important for diﬀerentiating the delete-
rious variations from neutral ones. The absolute value of the
ASA coeﬃcient was larger than that of the RSA in our model,
which might indicate that it is more meaningful to know the
real ASA values than the types of the residues as buried or ex-
posed (indicted by RSA) [47]. One possible reason is that ASA
could directly reﬂect the degree to which the residues are in
contact with the solvent molecules.
4.2.3. Sequence-based features. DDG: The sequence infor-
mation can be used to eﬀectively predict the changes of the
protein stability for single site mutations [16]. In our model,
the LDA analysis indicated that DDG was not predominant
in classifying disease-causing ones from neutral variations
(coeﬃcient = 0.225).
4.2.4. Other features. DISpro uses a one-dimensional
recursive neutral network (1D-RNN) to predict the probability
whether the residues are disordered or not with threshold of
0.5. Although originally the DISpro scores were not used to
diﬀerentiate the deleterious nsSNPs from the neutral ones, they
were a good predictor in the models (coeﬃcient = 0.386) sur-
prisingly [34].
Bulkiness was deﬁned as the ratio of the volume to the
length of a side chain, providing a measure of the average cross
section of the chain [48]. It was easy to see from Eq. (1) that the
absolute value of the coeﬃcient for Bulkiness was similar with
the Site Entropy (0.341 and 0.341), which indicate that the
Bulkiness is the same important as the RSA. Moreover, it
was ﬁrstly testiﬁed that three amino acid scales, i.e., the polar-
ity (PZ), OMH, and free energy (FE), were useful for improv-
ing the predictive power of the models. From above analyses,
the ten features were optimized alternantely using the LDA
method.
Using RPLS and LDA models, 28 nsSNPs were always pre-
dicted to be deleterious based on the phylogenetic features in
conjunction with the structure information and other simple
amino acid features. As shown in Table 4, the 19 deleterious
nsSNPs may occur in the helix sections, and nine of them
may occur in the transmembranes, e.g., A374T in ABCB3,
L293V in ABCB6, R304C in ABCB8. It was seen that the fre-
quency of occurrence of the deleterious nsSNPs in transmem-
brane (TM) regions was larger than those of the extracellular
and intracellular loop regions. It may be that the tiny changes
of properties in the amino acids are inclined to induce the
changes in TM structure [18]. Moreover, several deleterious
nsSNPs may occur near the ATPase binding sections of ABCB
transporters, e.g., G1063A in ABCB1; P576L in ABCB2;
A1100T in ABCB4; S560C in ABCB8; R432T in the ABCB11.
This subset of nsSNPs in ABCB transporters we predicted
would be best candidate nsSNPs for further investigation of
genotype and phenotype, as well as their role on the pathogen-
esis of speciﬁc human conditions in experiments.
In addition, two facts about the variation occurring in the
transporters were observed in our results. Firstly, the distribu-
tions of all 20 amino acids were found to be greatly diﬀerentbetween deleterious and neutral variations as shown in
Fig. 1. Interestingly, those results were diﬀerent from the statis-
tical results about the relative mutability of amino acids in the
Swiss-Prot database [31], and the top-eight amino acids were
N, S, D, E, A, T, I and M. Secondly, the amino acid compo-
sition of variations of the two training sets were also diﬀerent.
For example, the most variation rates in the neutral sets were
from I to V (or from V to I), from A to T, and from D to N;
however, they were the rates from L to P (or from P to L),
from K to E, from M to T, and from R to W in the deleterious
sets. Those results indicate that the two facts may be the spe-
ciﬁc characteristic only belonging to the transporters, which
may be diﬀerent from the general proteins.
In conclusion, we have ﬁrstly and systemically reﬁned a ser-
ies of features for analyzing the deleterious variations in the
transporters and predicting the deleterious nsSNPs in the
ABCB transporters using RPLS and LDA methods. The mod-
els built in this work would be applicable for predicting the
deleterious nsSNPs of other transporters. Moreover, many
indices, including the SIFT, ASA, DISpro, RSA, Site Entropy,
Bulkiness, DDG, Polarity, free energy and OMH, were demon-
strated to be useful for identifying the deleterious variations
from neutral ones in the LDA models. Twenty-eight possibly
deleterious nsSNPs in ABCB subfamily were also identiﬁed,
which would be helpful for further genotype–phenotype
researches as well as the pharmacogenetics study of transport-
ers.
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